Literature DB >> 26678471

Methylene Blue: Magic Bullet for Vasoplegia?

Leila Hosseinian1, Menachem Weiner, Matthew A Levin, Gregory W Fischer.   

Abstract

Methylene blue (MB) has received much attention in the perioperative and critical care literature because of its ability to antagonize the profound vasodilation seen in distributive (also referred to as vasodilatory or vasoplegic) shock states. This review will discuss the pharmacologic properties of MB and review the critical care, liver transplantation, and cardiac anesthesia literature with respect to the efficacy and safety of MB for the treatment of shock. Although improved blood pressure has consistently been demonstrated with the use of MB in small trials and case reports, better oxygen delivery or decreased mortality with MB use has not been demonstrated. Large randomized controlled trials are still necessary to identify the role of MB in hemodynamic resuscitation of the critically ill.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26678471     DOI: 10.1213/ANE.0000000000001045

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  10 in total

1.  ATHOS-3 and the knights of the round table-the search for the holy grail of vasopressors.

Authors:  Michael Hessler; Philip-Helge Arnemann; Laura Seidel; Tim Kampmeier; Sebastian Rehberg; Christian Ertmer
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 2.  Targeting mitochondrial dysfunction in CNS injury using Methylene Blue; still a magic bullet?

Authors:  Hemendra J Vekaria; Lora Talley Watts; Ai-Ling Lin; Patrick G Sullivan
Journal:  Neurochem Int       Date:  2017-04-07       Impact factor: 3.921

Review 3.  Medication and Fluid Management of Pediatric Sepsis and Septic Shock.

Authors:  Lauren Burgunder; Caroline Heyrend; Jared Olson; Chanelle Stidham; Roni D Lane; Jennifer K Workman; Gitte Y Larsen
Journal:  Paediatr Drugs       Date:  2022-03-21       Impact factor: 3.022

4.  Methylene Blue Reduces Fluid Loading and Norepinephrine Requirements for Post-Resuscitation Syndrome in a Pig Model of Refractory Cardiac Arrest Resuscitated with Veno-Arterial ECMO.

Authors:  Benjamin Pequignot; Mickael Lescroart; Sophie Orlowski; Nathan Reynette; Bana Martini; Eliane Albuisson; Héloise Pina; N'Guyen Tran; Daniel Grandmougin; Bruno Levy
Journal:  J Clin Med       Date:  2022-04-29       Impact factor: 4.964

5.  Severe Undifferentiated Vasoplegic Shock Refractory to Vasoactive Agents Treated with Methylene Blue.

Authors:  Farheen Manji; Benjamin Wierstra; Juan Posadas
Journal:  Case Rep Crit Care       Date:  2017-10-02

6.  Refractory vasodilatory shock secondary to metformin overdose supported with VA ECMO.

Authors:  Crystal Ives Tallman; Yu Zhang; Nicholas Black; Kara Lynch; Mohamed Fayed; Patil Armenian
Journal:  Toxicol Rep       Date:  2021-12-21

7.  Methylene blue for vasodilatory shock in the intensive care unit: a retrospective, observational study.

Authors:  Emily E Naoum; Adam A Dalia; Russel J Roberts; Lauren T Devine; Jamel Ortoleva
Journal:  BMC Anesthesiol       Date:  2022-06-27       Impact factor: 2.376

8.  Successful treatment of intravenous drug abuser with refractory vasoplegic syndrome after mitral valve repair for infective endocarditis.

Authors:  Jacob Lambert; Jw Awori Hayanga; Steven Turley; Paul McCarthy; Muhammad Salman; Galen Kabulski; Roy Henrickson; Christopher Cook; Heather K Hayanga
Journal:  SAGE Open Med Case Rep       Date:  2021-06-03

Review 9.  Angiotensin II: a new therapeutic option for vasodilatory shock.

Authors:  Rachel L Bussard; Laurence W Busse
Journal:  Ther Clin Risk Manag       Date:  2018-07-26       Impact factor: 2.423

10.  The additional use of methylene blue has a decatecholaminisation effect on cardiac vasoplegic syndrome after cardiac surgery.

Authors:  Walter Petermichl; Michael Gruber; Ina Schoeller; Kwahle Allouch; Bernhard M Graf; York A Zausig
Journal:  J Cardiothorac Surg       Date:  2021-07-28       Impact factor: 1.637

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.